Buy para-Methoxymethamphetamine (4-methoxy-N) Cas 22331-70-0

para-Methoxymethamphetamine (PMMA), also known as 4-methoxy-N-methylamphetamine (4-MMA), is a serotonergic drug of the amphetamine family related to para-methoxyamphetamine (PMA).^[1][3] It is the 4-methoxy analogue of methamphetamine.^[1][3]

Little is known about the pharmacological properties, metabolism, and toxicity of PMMA; because of its structural similarity to PMA, which has known toxicity in humans, it is thought to have considerable potential to cause harmful side effects or death in overdose.^[4] In the early 2010s, a number of deaths in users of the drug MDMA were linked to misrepresented tablets and capsules of PMMA.^[5]

PMMA is a serotonin–norepinephrine releasing agent (SNRA)^[6][7][8][9] as well as potent monoamine oxidase inhibitor (MAOI).^[10] It has a reduced tendency to produce severe hyperthermia at low doses compared to PMA,^[11][12] but at higher doses, side effects and risk of death become similar to those of PMA.^[13]

The synthesis and effects of PMMA were described by American experimental chemist Alexander Shulgin in his book PiHKAL, where it is referred to by the name “methyl-MA”, as the N-methylated form of 4-MA (PMA).^[1]

According to Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved), the effects of PMMA at a dose of 110 mg orally included tachycardia, compulsive yawning, and nystagmus, among others.^[1] It was said to have some of the physical side effects of the entactogen MDMA but none of its central effects.^[1] No psychedelic-like effects were mentioned.^[1]

PMMA is a monoamine releasing agent (MRA).^[6][7][8][9] The drug’s EC₅₀Tooltip half-maximal effective concentration values for induction of monoamine release in rat brain synaptosomes have been reported for the individual enantiomers of PMMA.^[6][7][8] In the case of (S)-PMMA, they were 41 nM for serotonin, 147 nM for norepinephrine, and 1,000 nM for dopamine, whereas for (R)-PMMA, they were 134 nM for serotonin, >14,000 nM for norepinephrine, and 1,600 nM for dopamine.^[6][7][8] Hence, PMMA appears to be a serotonin–norepinephrine releasing agent (SNRA) with weak effects on dopamine release.^[6][7][8][9] The drug has been found to strongly release serotonin and to weakly release dopamine in the brain in rodents